Biomerica to Present Real-World inFoods IBS Study Showing 59.6% Pain Reduction
Biomerica’s real-world study on its inFoods IBS guided diagnostic therapy has been accepted for presentation at Digestive Disease Week 2026 in Chicago. The upcoming poster will present data showing 59.6% of treated patients achieved FDA abdominal pain reduction endpoints versus 42.1% in controls.
1. Study Acceptance
Biomerica announced that an abstract evaluating real-world clinical effectiveness of its inFoods IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week 2026 in Chicago, scheduled May 2–5, 2026. The poster session will be displayed May 2 at 12:30 pm CT at McCormick Place.
2. Study Details
The real-world analysis builds on a multicenter, double-blinded, placebo-controlled trial and will report that 59.6% of patients in the treatment group met the FDA’s abdominal pain reduction endpoint versus 42.1% in the control group, with parallel improvements in IBS-C (67.1% vs. 35.8%) and IBS-M (66% vs. 29.5%).
3. Implications for Biomerica
Acceptance at the world’s largest GI conference underscores growing interest in non-pharmaceutical, precision dietary therapies and could enhance Biomerica’s profile among gastroenterology specialists, potentially accelerating adoption of its inFoods IBS test within a $30 billion total addressable market.